CompletedNCT03809325
Patient and Care Team Experiences With Three-Month Paliperidone
About this title
Read the official source —Observational studyAges 18+Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- Brussels and 40 more locationsSee all locations and recruitment
Study information
Study start dateStarted: November 21, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 225
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT03809325
- Official title
Show the full official title
Cross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
Get this study by email
Recruitment & locations
CompletedBrussels, Belgium · Asnières-sur-Seine, France · Cagnes-sur-Mer, France
38 more locations
- Dax, France
- Limoges, France
- Metz, France
- Montauban, France
- Montpellier, France
- Nice, France
- Novillars, France
- Rennes, France
- Toulon, France
- Berlin, Germany
- München, Germany
- Wasserburg A. Inn, Germany
- Cegléd, Hungary
- Celldömölk, Hungary
- Nagykálló, Hungary
- Szekszárd, Hungary
- Bolzano, Italy
- Brescia, Italy
- Frosinone, Italy
- Genzano di Roma, Italy
- Oliveto Citra, Italy
- Statte, Italy
- A Coruña, Spain
- Alcobendas, Spain
- Arganda, Spain
- Carmona, Spain
- Madrid, Spain
- Mairena del Aljarafe, Spain
- Manresa, Spain
- Sabadell, Spain
- Torrevieja, Spain
- Valencia, Spain
- Valladolid, Spain
- Vitoria-Gasteiz, Spain
- Zaragoza, Spain
- Birmingham, United Kingdom
- Leicester, United Kingdom
- London, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone Palmitate 3-Month Formulation (PP3M).
Who was this study for?
Listed age limits: from 18 years.
